Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brow Lifting With Dysport
NCT01401803Phase 4Completed
- Start
- Sep 2011
- Primary completion
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in Brow ptosis and blepharoptosis. Primary endpoint: Correction of brow ptosis with dysport injection at 6 months. Started Sep 2011; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Brow ptosisblepharoptosis
Beyond the preview
Go deeper on NCT01401803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01401803.